| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIF1A |
| Uniprot No | Q12756 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIF1A重组蛋白的3篇代表性文献摘要概括：
1. **文献名称**：*Structural basis for the ATP-induced reorganization of the KIF1A microtubule-binding motor domain*
**作者**：Kikkawa, M., et al.
**摘要**：通过重组表达KIF1A的微管结合结构域，结合X射线晶体学分析，揭示了ATP结合诱导的构象变化，阐明了其驱动蛋白运动循环的分子机制。
2. **文献名称**：*Recombinant KIF1A purification and functional characterization in axonal vesicle transport*
**作者**：Hirokawa, N., et al.
**摘要**：利用大肠杆菌重组表达系统纯化KIF1A蛋白，通过体外微管滑动实验和神经元模型，证实其作为单体驱动蛋白在突触囊泡运输中的关键作用。
3. **文献名称**：*Disease-associated mutations in the kinesin motor domain of KIF1A impair axonal transport*
**作者**：Lee, J.R., et al.
**摘要**：通过重组表达携带神经疾病相关突变的KIF1A蛋白，结合活细胞成像和单分子分析，揭示突变导致运动功能缺陷及轴突运输障碍的分子机制。
(注：以上文献信息为示例，实际引用需根据具体论文数据库核实。)
KIF1A recombinant protein is a genetically engineered form of the kinesin family member 1A (KIF1A), a microtubule-dependent motor protein critical for intracellular transport in neurons. Discovered in the 1990s, KIF1A belongs to the kinesin-3 subfamily and is primarily expressed in the nervous system. It plays a pivotal role in anterograde transport of synaptic vesicle precursors, neurotransmitters, and other cargoes along axons, ensuring proper synaptic function and neuronal communication. Mutations in the KIF1A gene are linked to neurodegenerative disorders such as hereditary spastic paraplegia (SPG30), sensory neuropathy, and encephalopathy.
Recombinant KIF1A is produced using expression systems like E. coli, insect cells, or mammalian cells, enabling controlled study of its structure-function relationships. The protein typically includes functional domains such as the N-terminal motor domain (for ATP hydrolysis and microtubule binding), a coiled-coil stalk (for dimerization), and a C-terminal cargo-binding domain. Researchers often engineer tags (e.g., His-tag, GST) for purification and tracking.
This recombinant tool has become indispensable for investigating molecular mechanisms of axonal transport, synaptic plasticity, and neurodegeneration. It facilitates in vitro assays to analyze motility, cargo interactions, and the impact of disease-associated mutations. Recent studies also explore its potential in drug screening for KIF1A-related disorders and as a component of gene therapy strategies. Advances in cryo-EM and single-molecule imaging using recombinant KIF1A have provided unprecedented insights into kinesin mechanics, aiding the development of targeted therapies for neurological diseases.
×
